Hyaluronic acid-modified NPs can interact with CD44 and receptors for hyaluronate mediated motility, which are overexpressed on the surface of a variety of tumor cells, while it also can be degraded by hyaluronidase around the tumor. The gene discussed is CD44; the disease is neoplasm.